A new drug takes 10 to 15 years on average from target discovery to FDA approval. In this long cycle, the quality of early research compounds downstream — choose the right target, and clinical success probability rises. The problem is that life-sciences researchers face not a single task, but constant back-and-forth between literature, databases, experimental data, and evolving hypotheses — fragmented process, hard to scale.

On April 16, OpenAI released GPT-Rosalind, its first reasoning model specifically for the life-sciences domain. As the name suggests, this pays tribute to Rosalind Franklin — the British chemist who revealed DNA's double-helix structure through X-ray diffraction, but was long underestimated. The model is specifically optimized for biology, drug discovery, and translational medicine workflows, combined with stronger tool-use capability, able to perform deep reasoning on complex tasks like chemical molecular reactions, protein structure and mutation effects, genomic sequence interpretation.

On technical metrics, GPT-Rosalind leads in life-sciences-specific benchmarks like BixBench. More noteworthy is its workflow design: the model can call over 50 scientific tools and databases, completing literature review, sequence-to-function interpretation, experimental planning, data analysis and other multi-step tasks. Partners include Amgen, Moderna, Allen Institute, Thermo Fisher Scientific and other top institutions, currently opened as a research preview in ChatGPT, Codex, and API via the trusted access program.

This is OpenAI's first domain-specific model for a particular scientific vertical. Before this, general large models like Claude, Gemini have been widely used in research scenarios, but life sciences' demands for precision and domain knowledge are extremely high, and general models often fall short on tool calling and long-horizon scientific reasoning. GPT-Rosalind's emergence shows that LLM applications in research are moving from "can do anything" to "does certain domains better."

Vertical specialization may become a watershed for the next stage of LLM competition. When general-capability ceilings are repeatedly approached, deep optimization for high-value vertical scenarios — specialized data, specialized toolchains, specialized evaluation standards — may be what truly differentiates.